{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:54:18Z","timestamp":1790830458540,"version":"4.1.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T00:00:00Z","timestamp":1431302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0125954","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T19:07:12Z","timestamp":1431371232000},"page":"e0125954","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":34,"title":["A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct01264445","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gloria","family":"Omosa-Manyonyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Mpendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Ruzagira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kilembe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elwyn","family":"Chomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Bourguignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Koutsoukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Collard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagna","family":"Laufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwynn","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Cormier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Len","family":"Dally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burc","family":"Barin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Ackland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Syvertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devika","family":"Zachariah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaal","family":"Anas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Sayeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Gilmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Priddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,5,11]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/QAD.0b013e328353bcaf","article-title":"CD8(+) T cells in preventing HIV infection and disease","volume":"26","author":"AB McDermott","year":"2012","journal-title":"AIDS"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1128\/JVI.68.7.4650-4655.1994","article-title":"Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome","volume":"68","author":"RA Koup","year":"1994","journal-title":"J Virol"},{"issue":"16","key":"ref3","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1073\/pnas.0611244104","article-title":"HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype","volume":"104","author":"A Saez-Cirion","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"7828","DOI":"10.4049\/jimmunol.0803928","article-title":"Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses","volume":"182","author":"A Saez-Cirion","year":"2009","journal-title":"J Immunol"},{"issue":"5403","key":"ref5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1126\/science.283.5403.857","article-title":"Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes","volume":"283","author":"JE Schmitz","year":"1999","journal-title":"Science"},{"issue":"7348","key":"ref6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine","volume":"473","author":"SG Hansen","year":"2011","journal-title":"Nature"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/cid\/ciq160","article-title":"An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers","volume":"52","author":"E Van Braeckel","year":"2011","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"36","key":"ref8","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1016\/j.vaccine.2013.05.021","article-title":"Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine","volume":"31","author":"E Van Braeckel","year":"2013","journal-title":"Vaccine"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"e41936","DOI":"10.1371\/journal.pone.0041936","article-title":"A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults","volume":"7","author":"MC Keefer","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/infdis\/jiu485","article-title":"Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans","volume":"211","author":"LR Baden","year":"2015","journal-title":"The Journal of infectious diseases"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1086\/509259","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine","volume":"194","author":"BS Graham","year":"2006","journal-title":"The Journal of infectious diseases"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1086\/587993","article-title":"Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag\/pol\/nef vaccine in healthy adults","volume":"46","author":"FH Priddy","year":"2008","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"7383","key":"ref13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature10766","article-title":"Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys","volume":"482","author":"DH Barouch","year":"2012","journal-title":"Nature"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1172\/JCI75894","article-title":"HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial","volume":"124","author":"PA Bart","year":"2014","journal-title":"J Clin Invest"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"e1000067","DOI":"10.1371\/journal.pmed.1000067","article-title":"Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials","volume":"6","author":"M Sarzotti-Kelsoe","year":"2009","journal-title":"PLoS Med"},{"key":"ref16","unstructured":"Stiles T, Grant V, Mawbey T. Good Clinical Laboratory Practice (GCLP). A quality sytem for laboratories that undertake the analysis of samples from clinical trials. Assurance BAoRQ, editor: BARQA ISBN 978-1-904610-00-7; 2010. 1\u201317 p."},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/CVI.00326-08","article-title":"Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents","volume":"16","author":"MJ Boaz","year":"2009","journal-title":"Clinical and vaccine immunology: CVI"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"e14330","DOI":"10.1371\/journal.pone.0014330","article-title":"Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories","volume":"5","author":"DK Gill","year":"2010","journal-title":"PLoS ONE"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1086\/650492","article-title":"Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates","volume":"201","author":"A Spentzou","year":"2010","journal-title":"The Journal of infectious diseases"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/JCM.41.11.5046-5052.2003","article-title":"Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors","volume":"41","author":"MC Sprangers","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.chom.2012.09.008","article-title":"A Blueprint for HIV Vaccine Discovery","volume":"12","author":"DR Burton","year":"2012","journal-title":"Cell host & microbe"},{"issue":"6136","key":"ref22","doi-asserted-by":"crossref","first-page":"1232910","DOI":"10.1126\/science.1232910","article-title":"Accelerating next-generation vaccine development for global disease prevention","volume":"340","author":"WC Koff","year":"2013","journal-title":"Science"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nri2890","article-title":"The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors","volume":"11","author":"RA Koup","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1600-065X.2010.00968.x","article-title":"Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV","volume":"239","author":"G Makedonas","year":"2011","journal-title":"Immunol Rev"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2010.09.011","article-title":"Induction of immunity to human immunodeficiency virus type-1 by vaccination","volume":"33","author":"MJ McElrath","year":"2010","journal-title":"Immunity"},{"issue":"9653","key":"ref26","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"SP Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"ref27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study","volume":"11","author":"GE Gray","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"22","key":"ref28","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"SM Hammer","year":"2013","journal-title":"N Engl J Med"},{"issue":"9653","key":"ref29","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis","volume":"372","author":"MJ McElrath","year":"2008","journal-title":"Lancet"},{"issue":"23","key":"ref30","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"S Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.4049\/jimmunol.1102756","article-title":"The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope","volume":"188","author":"MS de Souza","year":"2012","journal-title":"J Immunol"},{"issue":"8","key":"ref32","doi-asserted-by":"crossref","first-page":"e43396","DOI":"10.1371\/journal.pone.0043396","article-title":"MRKAd5 HIV-1 Gag\/Pol\/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load","volume":"7","author":"H Janes","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"e20479","DOI":"10.1371\/journal.pone.0020479","article-title":"Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study","volume":"6","author":"F Li","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nm.2316","article-title":"Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial","volume":"17","author":"M Rolland","year":"2011","journal-title":"Nat Med"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1128\/JVI.02030-10","article-title":"HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function","volume":"85","author":"MF Chevalier","year":"2011","journal-title":"J Virol"},{"issue":"5342","key":"ref36","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1126\/science.278.5342.1447","article-title":"Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia","volume":"278","author":"ES Rosenberg","year":"1997","journal-title":"Science"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3054","article-title":"Harnessing CD4(+) T cell responses in HIV vaccine development","volume":"19","author":"H Streeck","year":"2013","journal-title":"Nat Med"},{"issue":"8","key":"ref38","doi-asserted-by":"crossref","first-page":"e21225","DOI":"10.1371\/journal.pone.0021225","article-title":"A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)","volume":"6","author":"GJ Churchyard","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"ref39","doi-asserted-by":"crossref","first-page":"e12873","DOI":"10.1371\/journal.pone.0012873","article-title":"Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa","volume":"5","author":"W Jaoko","year":"2010","journal-title":"PLoS ONE"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1086\/650299","article-title":"A Phase I\/II Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus-type 5 Boost Vaccine in HIV Uninfected East Africans (RV 172)","volume":"201","author":"H Kibuuka","year":"2010","journal-title":"The Journal of infectious diseases"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nprot.2006.1","article-title":"Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression","volume":"1","author":"PK Chattopadhyay","year":"2006","journal-title":"Nat Protoc"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm1292","article-title":"Direct access to CD4+ T cells specific for defined antigens according to CD154 expression","volume":"11","author":"M Frentsch","year":"2005","journal-title":"Nat Med"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1128\/IAI.68.5.3002-3006.2000","article-title":"Depressed CD40 ligand expression contributes to reduced gamma interferon production in human tuberculosis","volume":"68","author":"B Samten","year":"2000","journal-title":"Infection and immunity"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"8185","DOI":"10.4049\/jimmunol.177.11.8185","article-title":"Antigen-specific central memory CD4+ T lymphocytes produce multiple cytokines and proliferate in vivo in humans","volume":"177","author":"M Stubbe","year":"2006","journal-title":"J Immunol"},{"issue":"22","key":"ref45","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1016\/j.vaccine.2013.10.030","article-title":"Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study","volume":"32","author":"T Harrer","year":"2014","journal-title":"Vaccine"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1128\/JVI.00138-10","article-title":"Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime\/boost vaccination","volume":"84","author":"SA Freel","year":"2010","journal-title":"J Virol"},{"issue":"12","key":"ref47","doi-asserted-by":"crossref","first-page":"6835","DOI":"10.1128\/JVI.00437-12","article-title":"Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted\/founder virus replication","volume":"86","author":"SA Freel","year":"2012","journal-title":"J Virol"},{"issue":"4","key":"ref48","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/infdis\/jis379","article-title":"Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection","volume":"206","author":"H Yang","year":"2012","journal-title":"The Journal of infectious diseases"},{"issue":"3","key":"ref49","doi-asserted-by":"crossref","first-page":"e90378","DOI":"10.1371\/journal.pone.0090378","article-title":"Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults","volume":"9","author":"J Kopycinski","year":"2014","journal-title":"PLoS One"},{"issue":"43","key":"ref50","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1016\/j.vaccine.2010.08.035","article-title":"Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems","volume":"28","author":"I Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"issue":"32","key":"ref51","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"DH Barouch","year":"2011","journal-title":"Vaccine"},{"issue":"8","key":"ref52","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/00002030-200405210-00019","article-title":"Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector","volume":"18","author":"S Kostense","year":"2004","journal-title":"AIDS"},{"issue":"15","key":"ref53","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"R Vogels","year":"2003","journal-title":"J Virol"},{"issue":"3","key":"ref54","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"RD Antrobus","year":"2014","journal-title":"Mol Ther"},{"issue":"11","key":"ref55","doi-asserted-by":"crossref","first-page":"e78679","DOI":"10.1371\/journal.pone.0078679","article-title":"A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age","volume":"8","author":"A Ouedraogo","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"ref56","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1128\/JVI.02058-12","article-title":"Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors","volume":"87","author":"P Penaloza-MacMaster","year":"2013","journal-title":"J Virol"},{"issue":"12","key":"ref57","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.4161\/hv.26038","article-title":"Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults","volume":"9","author":"CB Creech","year":"2013","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"6179","key":"ref58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1250672","article-title":"Immunology. Immune activation with HIV vaccines","volume":"344","author":"AS Fauci","year":"2014","journal-title":"Science"},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"N Frahm","year":"2012","journal-title":"J Clin Invest"},{"issue":"50","key":"ref60","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"DE Zak","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"ref61","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.vaccine.2014.10.017","article-title":"Use of placebos in Phase 1 preventive HIV vaccine clinical trials","volume":"33","author":"Y Huang","year":"2015","journal-title":"Vaccine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0125954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T02:35:04Z","timestamp":1599014104000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0125954"}},"subtitle":[],"editor":[{"given":"T. Mark","family":"Doherty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,11]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0125954","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,11]]}}}